About this item:

447 Views | 0 Downloads

Author Notes:

Young-sup Yoon, Division of Cardiology, Department of Medicine, Emory University School of Medicine, 1639 Pierce Drive, WMRB 3309, Atlanta, GA 30322, USA. E-mail: yyoon5@emory.edu

The authors indicate no potential conflict of interest.

Subjects:

Research Funding:

NIH grants DP3DK094346, RC1GM092035

NIH contract, HHSN268201000043C (Program of Excellence in Nanotechnology Award)

Wallace H. Coulter Translational Research Grant

Pilot grant of Emory-Georgia Tech Regenerative Medicine

NSF-EBICS (Emergent Behaviors of Integrated Cellular Systems) grant, CBET-0939511

Stem Cell Research Center of the 21st Century Frontier Research Program grant SC4300, funded by the Ministry of Science and Technology, Republic of Korea

Keywords:

  • cell therapy
  • cardiovascular disease
  • bone marrow
  • haematopoietic
  • paracrine
  • transdifferentiation
  • CD31
  • neovascularization
  • angiogenesis
  • vasculogenesis

Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells

Tools:

Journal Title:

British Journal of Pharmacology

Volume:

Volume 169, Number 2

Publisher:

, Pages 290-303

Type of Work:

Article | Post-print: After Peer Review

Abstract:

Cell-based therapy has emerged as a promising therapy for cardiovascular disease. Particularly, bone marrow (BM)-derived cells have been most extensively investigated and have shown encouraging results in preclinical studies. Clinical trials, however, have demonstrated split results in post-myocardial infarction cardiac repair. Mechanistically, transdifferentiation of BM-derived cells into cardiovascular tissue demonstrated by earlier studies is now known to play a minor role in functional recovery, and humoral and paracrine effects turned out to be main mechanisms responsible for tissue regeneration and functional recovery. With this advancement in the mechanistic insight of BM-derived cells, new efforts have been made to identify cell population, which can be readily isolated and obtained in sufficient quantity without mobilization and have higher therapeutic potential. Recently, haematopoietic CD31+ cells, which are more prevalent in bone marrow and peripheral blood, have been revealed to have angiogenic and vasculogenic activities and strong potential for therapeutic neovascularization in ischaemic tissues. This article will cover the recent advances in BM-derived cell-based therapy and implication of CD31+ cells.LINKED ARTICLES This article is part of a themed section on Regenerative Medicine and Pharmacology: A Look to the Future. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-2

Copyright information:

British Journal of Pharmacology © 2013 The British Pharmacological Society

Export to EndNote